Published in Vaccine Weekly, July 12th, 2006
According to researchers in Japan and the United States, "The product of Wilms' tumor gene 1 (WT1) is overexpressed in diverse human tumors, including leukemia, lung, and breast cancer, and is often recognized by antibodies in the sera of patients with leukemia. Since WT1 encodes MHC class I-restricted peptides recognized by cytotoxic T lymphocytes (CTL), WT1 has been considered as a promising tumor-associated antigen (TAA) for developing anticancer immunotherapy....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly